Business Wire

PANASONIC

1.7.2020 12:02:06 CEST | Business Wire | Press release

Share
Berlin’s First Smart City Quarter Powered by Panasonic

Panasonic is proud to announce the start of its innovative, CO2 -saving energy solution for the smart city project, Future Living® Berlin. The urban beacon is an important project in the company’s wider smart cities portfolio, which contribute to its focus on the decarbonization of society.

The installation in Berlin combines both green & sustainable and digital & connected living. It is realised through the installation of smart energy solutions including Panasonic’s highly efficient air to water heat pumps, photovoltaic (PV) panels and storage batteries integrated into an intelligent and efficient energy management system.

Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V comments,

‘We bring to the project over 60 years of heating and cooling expertise alongside decades in PV and battery solutions, and a passion for innovations that will shape the future for generations to come. ‘

Panasonic has achieved strong sales growth in the relevant Energy business areas in Europe, e.g. double-digit sales growth in the air to water heat pump business for the last 10 years. The company has also committed in 2019 to grow the “Residential Energy Saving Equipment” business multiple times over by 2025.

Efficient Energy Management

For Panasonic, Future Living® Berlin is a fundamentally important experiment in building cutting-edge energy solutions. The project marks a milestone in achieving the goals set in the strategy.

Panasonic’s energy experts and software engineers of its R&D Centre in Europe have developed an intelligent energy management solution to optimize the use of energy and couple electricity with the heating sector. The smart control combines heat pumps together with other efficient, green Panasonic technologies, such as PV panels. The technologies have been integrated into an efficient energy saving solution not only controlled, but also constantly optimised by Panasonic’s intelligent energy management solution.

Ralf Becker, Project Leader Energy Group, Panasonic R&D Centre Europe explains,

‘The solution is a world first, developed with leading research institutions for decentralized energy management. In simulations together with university test labs we achieved an improvement of used energy by up to 15%.‘

A Beacon for Sustainable Living

The core energy component of the Future Living Berlin green & sustainable goal is the installed Panasonic’s air to water heat pump product line-up, ‘Aquarea’. A highly energy efficient technology, they run almost carbon-free when powered by the renewable energy provided by the 600 Panasonic HIT panels, which supply a capacity of 195kWp. On account of the patented silicone technology, the Panasonic photovoltaic system is 10% more efficient than conventional modules. Furthermore Panasonic’s HIT technology achieves a significantly better performance in hot environments because of its superior temperature coefficient – an essential advantage in coping with the climate change.

Utilising the renewable energy, the air to water system is used for space heating and warm water generation. For increased performance, the heat pumps include a cloud-based connectivity feature for installers called Aquarea Service Cloud which makes them even more reliable. It saves further CO2 emissions as maintenance visits can be organized much more efficiently and partly even conducted remotely.

These energy solutions are brought together under a Aquarea Smart Cloud, which allows end-users to monitor their power usage and manage temperature settings accordingly. This results in increased efficiency and comfort while enjoying transparency of their consumption.

To achieve further sustainable and green objectives, residents are part of a wider ecological environment which offers green car sharing, shared washing machines, and Panasonic energy solutions

Connected comfortability

The digital & connected goal of Future Living Berlin starts within the residential apartments. The equipment follows the idea of being smart and connected with Panasonic TVs and smart speakers being part of an overall IoT infrastructure, which includes an apartment manager as the central hub.

Digital & connected solutions are further extended to include wider security, safety, and smart building solutions that enhance the overall comfortability of residents.

Suzuki continues,

‘Future Living® Berlin is a future Way of Living – of how we may live tomorrow with a focus on social, digital & connected, and green & sustainable living.’

Panasonic is partnering in the smart city project with GSW Sigmaringen, the building-owner of Future Living® Berlin.

About Panasonic

Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 61.9 billion Euro (7.49 trillion yen) for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. To learn more about Panasonic: https://www.panasonic.com/global

IMAGES TO DOWNLOAD: https://www.flickr.com/photos/panasonic-europe/collections/72157714840244853/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye